The FDA approved daraxonrasib, sold as Rasonque, for metastatic pancreatic cancer after a late-stage trial found the drug nearly doubled survival compared to standard chemotherapy. In the trial of 500 patients, those taking daraxonrasib had a median overall survival of about 13.2 months, versus roughly 6.6 to 6.7 months for those receiving chemotherapy.
Le Monde frames the approval similarly as a historic breakthrough, emphasizing the FDA statement, trial survival doubling, and the broader implications for targeting a previously 'undruggable' protein relevant to other cancers, with no distinct ideological slant.
Scientific American, BBC, and France 24 report the FDA approval as a major medical breakthrough, focusing on trial survival statistics, mechanism of action (targeting mutated KRAS), and expert quotes on its transformative potential; BBC adds context on disease mortality and the Ben Sasse trial participation.
The Daily Wire covers the approval with a similar celebratory tone, emphasizing trial data, FDA statement, expedited review timeline, and enthusiastic clinician quotes, along with detailed side-effect and mortality statistics; framing is factual and non-political aside from an unrelated 'Related' link about Fauci.